TRICOPAT
Unleash Your Hair's True Potential
The first device in the world that stops hair loss and promotes its regrowth
TRICOPAT® is the latest development in trichology for the treatment of male and female scalp pathologies, in a completely painless way and without injections.
The device uses the unique TRICOGENESI® methodology, which is backed by 2 global patents and marks an innovation that is 100% Italian.
The result of over 15 years of experience in the field of dermatology, TRICOPAT® was developed thanks to a research project performed at the Scientific and Technological Hub that is home to CNR, ENEA and the University of Bologna.
How does TRICOPAT work?
TRICOPAT® technology combines the simultaneous action of skin micro-incision and pressure waves to perform various dynamicrestructuring actions:
1. Immediate increase of blood microcirculation for tissue oxygenation
2. Stimulation of the tissue’s cellular metabolism
3. Delivery of active ingredients
Concentrates several dynamic restructuring actions in a single portable device weighing just 4.5 kg, including:
-
Controlled skin micro-incision
-
Pressure wave stimulation
-
Ionophoresis
-
Electrostimulation
-
Photostimulation
TRICOGENESI® methodology is developed by the association of TRICOPAT® and growth factors vehiculated with iontophoresis.
The result is a significant improvement of androgenetic alopecia both in male and female patients, with reduction of hair loss and an increased hair diameter in all the treated scalp areas.
The protocol consists of JUST
THE PROTOCOL CONSIST JUST 4 SESSIONS EVERY 3 WEEKS
RESULTS (after 6 months)
Clinical study
This technique represents a safe and useful option for treating and preventing androgenetic alopecia, by mechanisms that included activating fibroblasts and elastin at the scalp under wound healing conditions, pronging anagen phase regrowth of new hair by stimulation of the blood microcirculation and by the effect of growing factors.
Moreover, this procedure is simple for the operator and is extremely pleasant for the patient, with cost-effect ration very low. As this association targets multiple pathogenetic factors of AGA, we believe that this procedure should be offered to patients with AGA for a faster hair follicle stimulation.
